New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:38 EDTCPXXCelator announces data, recommendation to continue CPX-351 Phase 3 study
Celator Pharmaceuticals announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 clinical study of CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia has completed a planned safety review and recommended that the study should continue as planned without any modifications. The primary efficacy endpoint of the study is overall survival. The study is being conducted in the U.S. and Canada, with more than 40 leading cancer centers participating.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
07:06 EDTCPXXCelator Pharmaceuticals' CPX-351 granted Fast Track designation by FDA
Subscribe for More Information
January 12, 2015
09:30 EDTCPXXOn The Fly: Pre-market Movers
HIGHER: Foundation Medicine (FMI) up 138.9% following transaction with Roche (RHHBY)... Celator Pharmaceuticals (CPXX), up 19.1% after announcing promising Phase 2 data for CPX-351... Second Sight (EYES), up 16.7% after Health Canada approves Argus II retinal prosthesis system... Aegerion (AEGR), up 7.8% after reporting preliminary fourth quarter results and guidance... Express (EXPR), up 4.5% after reporting preliminary fourth quarter results. NOTABLE: NPS Pharmaceuticals (NPSP), up 8.5% following acquisition by Shire (SHPG)... Shire is down 1.1% in pre-market trading. LOWER: Arrowhead (ARWR), down 20.9% after FDA clears company to begin modified study of ARC-520 in a preliminary call of a partial clinical hold... Tiffany (TIF), down 10.4% after lowering fiscal 2014 net EPS guidance... SanDisk (SNDK), down 10.1% after lowering fourth quarter outlook... Ascena Retail (ASNA), down 5.8% after lowering fiscal 2015 adjusted EPS view... Sarepta Therapeutics (SRPT), down 5.9% after reporting long-term outcomes from Phase IIb Eteplirsen study... Loral Space & Communications (LORL), down 3.6% following a NY Post article that reported that talks to sell itself to the Ontario Teachers’ Pension Plan have ended... Southwestern Energy (SWN), down 4.2% after filing to sell 20.3M shares of stock and 26M depository shares.
07:01 EDTCPXXCelator Pharmaceuticals announces promising Phase 2 data for CPX-351
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use